GFAP and Alzheimer disease: To further test whether plasma and CSF GFAP levels were increased in the earliest stage of the preclinical AD continuum, we analyzed a group of individuals with a low burden of Aβ pathology, namely, a positive CSF Aβ42/40 ratio but Aβ PET centiloids lower than 3023 (eMethods in Supplement 1).